Abstract
We previously reported that angiotensin-converting enzyme inhibitors (ACE-Is) promote collateral circulation in patients with coronary artery disease (CAD). There have been many reports on the beneficial effects of angiotensin II type 1 receptor blockers (ARBs) on the cardiac microvasculature. Therefore, the following studies were performed to evaluate the association between treatment with an ARB and the enhancement of coronary collateral circulation as assessed by the Rentrop Score (RS) (Study 1) and to compare these results to those obtained with an ACE-I (Study 2). The subjects were 456 patients with angina who underwent coronary angiography. Study 1: Those who had one (1-V), two (2-V) or three significantly stenosed vessels (3-V) and who received only an ARB without any other anti-hypertensive medication were defined as the ARB group (n=81), and age-, sex- and body mass index–matched subjects (n=146) were selected as a comparative group. There were no significant differences in the percentage of patients with RS≥1 between the two groups. Study 2: Those who received an ACE-I as the only anti-hypertensive treatment were defined as the ACE-I group (n=67), which was matched to the ARB group in Study 1. The percentage of patients with RS≥1 in the ACE-I group was significantly higher than that in the ARB group as assessed by a Cochran-Mantel-Haenszel analysis. In addition, patients with 3-V disease who were treated with an ACE-I, but not an ARB, were most likely (odds ratio [confidence Interval]): 27.7 [4.8–161.0]) to show enhanced collateral circulation, as assessed by a multiple logistic regression analysis. These results suggest that treatment with an ACE-I, but not treatment with an ARB, was associated with the enhancement of collateral circulation in patients with CAD.
Similar content being viewed by others
Article PDF
References
Nelissen-Vrancken HJ, Debets JJ, Snoeckx LH, Daemen MJ, Smits JF : Time-related normalization of maximal coronary flow in isolated perfused hearts of rates with myocardial infarction. Circulation 1996; 93: 349–355.
Kocher AA, Schuster MD, Szabolcs MJ, et al: Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevent cardiomyocyte aptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430–436.
Suzuki H, Kanno Y, Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307–314.
Tamarat R, Silvestre JS, Kubis N, et al: Endothelial nitric oxide synthase lies downstream from angiotensin II–induced angiogenesis in ischemic hindlimb. Hypertension 2002; 39: 830–835.
Sasaki K, Murohara T, Ikeda H, et al: Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109: 603–611.
de Boer RA, Pinto YM, Suurmeijer AJ, et al: Increased expression of cardiac angiotensin II type 1 (AT1) receptors decrease myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 2003; 57: 434–442.
Cameron NE, Cotter MA, Robertson S : Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12–18.
Maxfield EK, Cameron NE, Cotter MA, Dines KC : Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993; 36: 1230–1237.
Olivetti G, Cigola E, Lagrasta C, et al: Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 21: 362–370.
Clozel JP, Kuhn H, Hefti F : Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989; 7: 267–275.
Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T : Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1997; 29: 478–482.
Miura S, Nishikawa H, Zhang B, Matuo Y : Angiotensin-converting enzyme inhibitor promotes coronary collateral circulation in patients with coronary artery disease. Circ J 2003; 67: 535–538.
Miura S, Matsuo Y, Saku K : Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003; 41: 1118–1123.
Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI : Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B2 receptor pathway. Circ Res 2001; 89: 678–683.
Rentrop KP, Cohen M, Blanke H, Phillips RA : Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5: 587–592.
Saku K, Zhang B, Ohta T, Arakawa K : Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999; 33: 436–443.
Saku K, Zhang B, Shirai K, Jimi S, Yoshinaga K, Arakawa K : Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary heart disease. J Am Coll Cardiol 1999; 34: 1443–1451.
SAS/STAT User's Guide, Version 6, Vol. 2, 4th ed. Cary, SAS Institute Inc, 1990, pp 891–1456.
Helfant RH, Vokonas PS, Gorlin R : Functional importance of the human coronary collateral circulation. N Engl J Med 1971; 284: 1277–1281.
Schieffer B, Wirger A, Meybrunn M, et al: Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994; 89: 2273–2282.
Sladek T, Sladkova J, Kolar F, et al: The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 1996; 31: 568–576.
Fujiyama S, Matsubara H, Nozawa Y, et al: Angiotensin AT1 and AT2 receptors differently regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding–epidermal growth factor (EGF)−mediated EGF receptor transactivation. Circ Res 2001; 88: 22–29.
Otani A, Takagi H, Suzuam K, Honda Y : Angiotensin II potentiates vascular endothelial growth factor–induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619–628.
Chua CC, Hamdy RC, Chua BH : Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187–194.
Imanishi T, Hano T, Nishio I : Angiotensin II potentiates vascular endothelial growth factor–induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 27: 101–108.
Shweiki D, Itin A, Soffer D, Keshet E : Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845.
Brogi E, Wu T, Namiki A, Isner JM : Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90: 649–652.
Fabre JE, Rivard A, Magner M, Silver M, Isner JM : Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99: 3043–3049.
Takai S, Jin D, Sakaguchi M, et al: Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens Res 2004; 27: 517–522.
Emaueli C, Salis MB, Stacca T, et al: Angiotensin AT1 receptor signaling modulates reparative angiogenesis induced by limb ischemia. Br J Pharmacol 2002; 135: 87–92.
Munzenmaier DH, Greene AS : Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27: 760–765.
van Royen N, Piek JJ, Buschmann I, et al: Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 543–553.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Imaizumi, S., Miura, Si., Nishikawa, H. et al. Angiotensin II Type 1 Receptor Blockers Do Not Promote Coronary Collateral Circulation in Patients with Coronary Artery Disease. Hypertens Res 29, 135–141 (2006). https://doi.org/10.1291/hypres.29.135
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.135